Hampel, P., Rabe, K., Maurer, M., Wang, Y., Kenderian, S., Muchtar, E., Roeker, L., Leis, J., Tsang, M., Hilal, T., Parrondo, R., Koehler, A., Bailen, R., Coddington, C., Behnken, A., Schwager, S., Hanson, C., Braggio, E., Shi, M., Mendoza, C., Slager, S., Kay, N., Parikh, S. (2025). Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL). Blood. https://doi.org/10.1182/blood-2025-5667